Free Trial

Sumitomo Mitsui Trust Group Inc. Has $45.22 Million Holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT)

Adaptive Biotechnologies logo with Medical background

Sumitomo Mitsui Trust Group Inc. decreased its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) by 10.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,085,690 shares of the company's stock after selling 747,447 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 4.10% of Adaptive Biotechnologies worth $45,217,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ADPT. Exchange Traded Concepts LLC bought a new position in shares of Adaptive Biotechnologies during the 1st quarter valued at $634,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Adaptive Biotechnologies during the 1st quarter valued at $87,000. GAMMA Investing LLC raised its holdings in shares of Adaptive Biotechnologies by 36.5% during the 1st quarter. GAMMA Investing LLC now owns 13,393 shares of the company's stock valued at $100,000 after purchasing an additional 3,583 shares in the last quarter. Alpha Wealth Funds LLC bought a new position in shares of Adaptive Biotechnologies during the 1st quarter valued at $297,000. Finally, Rhumbline Advisers raised its holdings in shares of Adaptive Biotechnologies by 4.0% during the 1st quarter. Rhumbline Advisers now owns 188,524 shares of the company's stock valued at $1,401,000 after purchasing an additional 7,322 shares in the last quarter. Hedge funds and other institutional investors own 99.17% of the company's stock.

Adaptive Biotechnologies Stock Up 4.3%

NASDAQ ADPT traded up $0.50 during midday trading on Friday, hitting $11.98. The company had a trading volume of 1,018,695 shares, compared to its average volume of 1,628,475. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -12.48 and a beta of 1.83. The firm has a fifty day simple moving average of $9.84 and a two-hundred day simple moving average of $8.32. Adaptive Biotechnologies Corporation has a fifty-two week low of $3.47 and a fifty-two week high of $12.43.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.08. The company had revenue of $52.44 million for the quarter, compared to analyst estimates of $42.13 million. Adaptive Biotechnologies had a negative net margin of 74.84% and a negative return on equity of 62.79%. The business's quarterly revenue was up 25.2% on a year-over-year basis. During the same period last year, the business posted ($0.33) EPS. As a group, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Adaptive Biotechnologies

In other news, insider Harlan S. Robins sold 68,412 shares of Adaptive Biotechnologies stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $7.35, for a total transaction of $502,828.20. Following the sale, the insider directly owned 1,279,524 shares in the company, valued at approximately $9,404,501.40. The trade was a 5.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.40% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ADPT shares. Craig Hallum started coverage on shares of Adaptive Biotechnologies in a report on Wednesday, June 18th. They set a "buy" rating and a $15.00 price target on the stock. The Goldman Sachs Group raised their price target on shares of Adaptive Biotechnologies from $9.00 to $10.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Piper Sandler reiterated an "overweight" rating and issued a $13.00 target price (up from $11.00) on shares of Adaptive Biotechnologies in a research note on Tuesday, May 6th. Finally, Morgan Stanley raised their target price on shares of Adaptive Biotechnologies from $7.00 to $9.00 and gave the company an "equal weight" rating in a research note on Monday, May 5th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, Adaptive Biotechnologies has a consensus rating of "Moderate Buy" and a consensus target price of $10.57.

Read Our Latest Research Report on Adaptive Biotechnologies

About Adaptive Biotechnologies

(Free Report)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

See Also

Institutional Ownership by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Should You Invest $1,000 in Adaptive Biotechnologies Right Now?

Before you consider Adaptive Biotechnologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.

While Adaptive Biotechnologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines